# BLRX catalysts: BioLineRx Ltd. PDUFA dates and FDA events

Canonical: https://sec-api.dev/companies/blrx/catalysts

> BioLineRx Ltd. (BLRX) has 1 upcoming catalyst. The next is the APHEXDA® (motixafortide) interim data readout, 1H 2027.

Data as of November 16, 2026 (snapshot 20261116T222116Z). Every date quotes the SEC filing or FDA page it came from. Date precision: month only, exact day, half-year only, year only.

**Free:** every drug page and the next 30 days of the FDA calendar, no account. Calendar API, alerts when a date moves, and full history: https://sec-api.dev/pricing . Free API key: https://sec-api.dev/sign-up?ref=ai-claudebot

## Verified answer

### What are the upcoming FDA catalysts for BLRX?

BioLineRx Ltd. (BLRX) has 1 upcoming catalyst. The next is the APHEXDA® (motixafortide) interim data readout, 1H 2027. Press release filed with the SEC (EX-99): "We are excited to advance GLIX1 development into this first-in-human clinical trial and look forward to initial data in the first half of 2027."" [Calendar and source filings](https://sec-api.dev/companies/blrx/catalysts)

Source: Press release filed with the SEC (EX-99), accession 0001178913-26-002262, https://www.sec.gov/Archives/edgar/data/1498403/000117891326002262/exhibit_1.htm (retrieved 2026-11-12). Last confirmed 2026-04-28. Cite: https://sec-api.dev/companies/blrx/catalysts#answer

## Company

| Field | Value |
| --- | --- |
| Name | BioLineRx Ltd. |
| Ticker | BLRX (Nasdaq) |
| SEC CIK | 1498403 |
| SIC | 2834 |
| SEC filings | https://sec-api.dev/companies/blrx |

## Catalysts

| Date | Event | Ticker | Indication | Status | Source sentence |
| --- | --- | --- | --- | --- | --- |
| May 2021 | [APHEXDA® (motixafortide) topline data readout](https://sec-api.dev/pdufa/motixafortide) | BLRX |  | completed, met | "Top-line results announced in May 2021 showed highly statistically significant evidence across all primary and secondary endpoints favoring motixafortide in combination with G-CSF (p<0.0001)." ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1498403/000117891324003823/exhibit_3.htm)) |
| Sep 2022 | [APHEXDA® (motixafortide) FDA approval](https://sec-api.dev/pdufa/motixafortide) | BLRX | multiple myeloma | completed, approved | "In September 2022, we submitted an NDA to the FDA for motixafortide in stem cell mobilization for autologous bone marrow transplantation for multiple myeloma patients and as noted above in September 2023, the FDA approved motixafortide in combination with G-CSF to mobilize hematopoietic stem cells to the peripheral blood for collection and subsequent autologous transplantation in patients with multiple myeloma." ([SEC Form 10-K](https://www.sec.gov/Archives/edgar/data/1498403/000117891325001123/zk2532907.htm)) |
| Sep 2022 | [APHEXDA® (motixafortide) NDA/BLA submission](https://sec-api.dev/pdufa/motixafortide) | BLRX | multiple myeloma | completed | "In September 2022, we submitted an NDA to the FDA for motixafortide in stem cell mobilization for autologous bone marrow transplantation for multiple myeloma patients and as noted above in September 2023, the FDA approved motixafortide in combination with G-CSF to mobilize hematopoietic stem cells to the peripheral blood for collection and subsequent autologous transplantation in patients with multiple myeloma." ([SEC Form 10-K](https://www.sec.gov/Archives/edgar/data/1498403/000117891325001123/zk2532907.htm)) |
| Sep 2023 | [APHEXDA® (motixafortide) trial start](https://sec-api.dev/pdufa/motixafortide) | BLRX |  | completed | "Reported preliminary data in September 2023 from single-arm pilot phase of the investigator-initiated Phase 2 combination trial in first-line PDAC." ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1498403/000117891326004331/exhibit_3.htm)) |
| September 8, 2023 | [APHEXDA® (motixafortide) FDA approval](https://sec-api.dev/pdufa/motixafortide) | BLRX | multiple myeloma | completed, approved | "In September 2023, the U.S. Food and Drug Administration ("FDA") approved motixafortide in stem cell mobilization for autologous transplantation for multiple myeloma patients, and the Company began to independently commercialize motixafortide in the U.S." ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1498403/000117891326004331/exhibit_2.htm)) |
| Nov 2023 | [APHEXDA® (motixafortide) trial start](https://sec-api.dev/pdufa/motixafortide) | BLRX |  | completed | "In November 2023, we initiated pivotal bridging study preparation activities with Gloria, our Asia partner, to support potential approval and commercialization of motixafortide in stem-cell mobilization in China." ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1498403/000117891326004331/exhibit_3.htm)) |
| Feb 2024 | [APHEXDA® (motixafortide) trial start](https://sec-api.dev/pdufa/motixafortide) | BLRX |  | completed | "First patient dosed in randomized study in February 2024." ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1498403/000117891326004331/exhibit_3.htm)) |
| 1H 2025 | [APHEXDA® (motixafortide) trial start](https://sec-api.dev/pdufa/motixafortide) | BLRX |  | scheduled | "Anticipate initiation of pivotal clinical trial in 1H 2025" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1498403/000117891324003823/exhibit_1.htm)) |
| Feb 2025 | [APHEXDA® (motixafortide) trial start](https://sec-api.dev/pdufa/motixafortide) | BLRX |  | completed | "First patient dosed in February 2025, with data planned in 2026*" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1498403/000117891326004331/exhibit_3.htm)) |
| May 30, 2025 | [BioLineRx Ltd. trial start](https://sec-api.dev/companies/blrx/catalysts) | BLRX |  | completed | "BioLineRx Ltd. (NASDAQ/TASE: BLRX), a development stage biopharmaceutical company pursuing life-changing therapies in oncology and rare disease, today announced that a poster including new data from the single-arm pilot phase of the investigator-initiated, randomized CheMo4METPANC Phase 2 combination clinical trial will be presented at the 2025 American Society of Clinical Oncology (ASCO) Annual Meeting, taking place May 30-June 3, 2025 in Chicago, Illinois." ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1498403/000117891325002019/exhibit_1.htm)) |
| Aug 2025 | [APHEXDA® (motixafortide) trial start](https://sec-api.dev/pdufa/motixafortide) | BLRX | recurrent and progressive glioblastoma | completed | "An IND application was cleared by the U.S. Food and Drug Administration (FDA) in August 2025, and in April 2026 the first patient was dosed in the first-in-human Phase 1/2 study GLIX1 for the treatment of recurrent and progressive glioblastoma (GBM) and other high-grade gliomas." ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1498403/000117891326004331/exhibit_3.htm)) |
| Dec 2025 | [APHEXDA® (motixafortide) trial start](https://sec-api.dev/pdufa/motixafortide) | BLRX |  | completed | "First patient dosed in December 2025" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1498403/000117891326004331/exhibit_3.htm)) |
| 2026 | [APHEXDA® (motixafortide) interim data readout](https://sec-api.dev/pdufa/motixafortide) | BLRX |  | scheduled | "Interim data planned for 2026 and full enrollment projected for 2027*" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1498403/000117891325003941/exhibit_3.htm)) |
| May 27, 2026 | [APHEXDA® (motixafortide) trial start](https://sec-api.dev/pdufa/motixafortide) | BLRX | Glioblastoma | completed | "- Announced first patient dosed in Phase 1/2a clinical trial of GLIX1 for treatment of glioblastoma (GBM) -" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1498403/000117891326002934/exhibit_1.htm)) |
| 1H 2027 | [APHEXDA® (motixafortide) interim data readout](https://sec-api.dev/pdufa/motixafortide) | BLRX |  | scheduled | "We are excited to advance GLIX1 development into this first-in-human clinical trial and look forward to initial data in the first half of 2027."" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1498403/000117891326002262/exhibit_1.htm)) |

## Drugs

- [APHEXDA® (motixafortide)](https://sec-api.dev/pdufa/motixafortide): multiple myeloma, recurrent and progressive glioblastoma, glioblastoma, stem-cell mobilization and solid tumors

## Feeds and downloads

- Subscribe (iCal): https://sec-api.dev/companies/blrx/catalysts.ics
- Next 30 days as CSV: https://sec-api.dev/fda-calendar.csv . JSON: https://sec-api.dev/fda-calendar.json . All events (iCal): https://sec-api.dev/fda-calendar.ics
- New or moved PDUFA dates: https://sec-api.dev/pdufa-dates/feed.xml (RSS), https://sec-api.dev/pdufa-dates/feed.json (JSON Feed)
- FDA approvals: https://sec-api.dev/fda-approvals-today/feed.xml (RSS), https://sec-api.dev/fda-approvals-today/feed.json (JSON Feed)
- License: CC BY 4.0 for the public 30-day window (https://sec-api.dev/biotech/license.txt). Full history: https://sec-api.dev/pricing

## Cite this page

sec-api.dev. "BLRX catalysts: BioLineRx Ltd. PDUFA dates and FDA events." Biotech catalyst calendar, data as of November 16, 2026 (snapshot 20261116T222116Z). https://sec-api.dev/companies/blrx/catalysts

```bibtex
@misc{secapidev_companies_blrx_catalysts_20261116,
  title        = {BLRX catalysts: BioLineRx Ltd. PDUFA dates and FDA events},
  author       = {{sec-api.dev}},
  year         = {2026},
  month        = {nov},
  howpublished = {\url{https://sec-api.dev/companies/blrx/catalysts}},
  note         = {Biotech catalyst calendar, data as of 2026-11-16, snapshot 20261116T222116Z. Compiled from SEC EDGAR filings, FDA and ClinicalTrials.gov; each date quotes its source.}
}
```

```json
{"type":"dataset","id":"secapidev_companies_blrx_catalysts_20261116","title":"BLRX catalysts: BioLineRx Ltd. PDUFA dates and FDA events","publisher":"sec-api.dev","URL":"https://sec-api.dev/companies/blrx/catalysts","issued":{"date-parts":[[2026,11,16]]},"version":"20261116T222116Z","license":"https://creativecommons.org/licenses/by/4.0/","note":"Compiled from SEC EDGAR filings, FDA and ClinicalTrials.gov; each date quotes its source."}
```

---
Independent. Not affiliated with, endorsed by, or sponsored by the U.S. Food and Drug Administration or the U.S. Securities and Exchange Commission. Dates are as stated by sponsors and FDA; the FDA can act before or after a target date. Not investment advice.
